Daehwa Pharmaceutical
Daehwa Pharmaceutical is a South Korea–based pharmaceutical company engaged in new drug R&D, formulation development, clinical development, and manufacture of prescription, over-the-counter, aesthetics and health supplement products. The company operates multiple manufacturing sites and a research campus, pursues global clinical programs and regulatory approvals (including FDA, EMA and overseas approvals), and maintains ISO-based compliance and ESG management systems.
Industries
Nr. of Employees
medium (51-250)
Daehwa Pharmaceutical
Patents
Pharmaceutical composition for oral administration comprising high concentration taxane
US-11020370-B2
View DetailsPharmaceutical composition for oral administration comprising high concentration taxane
US-10987335-B2
View DetailsPharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin
US-9956242-B2
View Details
Pharmaceutical composition for oral administration comprising high concentration taxane
US-11020370-B2
View DetailsPharmaceutical composition for oral administration comprising high concentration taxane
US-10987335-B2
View DetailsPharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin
US-9956242-B2
View DetailsProducts
리포락셀액 (DHP107)
Oral anticancer product (clinical development candidate referenced across multiple clinical phases and regulatory activities).
Hyaluronic-acid based filler (esthetic product)
Aesthetics filler product line marketed from a German-manufactured filler offering referenced on the company site.
Transdermal patch products (examples: 리바멘사 패치)
Transdermal/adhesive patch products developed and produced using TDDS capabilities; specific patch products are listed in historical approvals and product pages.
우아한 메가바이오틱스 (probiotic dietary supplements)
Probiotic / postbiotic supplement product line offered under the company's health-function food category.
록소나 첩부제
24시간 지속효과를 제공하는 록소프로펜 첩부제입니다.
하이로곤카타플라스마
관절염 및 통증 부위에 부착하여 사용하는 록소프로펜 계통의 카타플라스마 패치/플라스터 제품입니다.
리포락셀액 (DHP107)
Oral anticancer product (clinical development candidate referenced across multiple clinical phases and regulatory activities).
Hyaluronic-acid based filler (esthetic product)
Aesthetics filler product line marketed from a German-manufactured filler offering referenced on the company site.
Transdermal patch products (examples: 리바멘사 패치)
Transdermal/adhesive patch products developed and produced using TDDS capabilities; specific patch products are listed in historical approvals and product pages.
우아한 메가바이오틱스 (probiotic dietary supplements)
Probiotic / postbiotic supplement product line offered under the company's health-function food category.
록소나 첩부제
24시간 지속효과를 제공하는 록소프로펜 첩부제입니다.
하이로곤카타플라스마
관절염 및 통증 부위에 부착하여 사용하는 록소프로펜 계통의 카타플라스마 패치/플라스터 제품입니다.
Services
Joint research and R&D network collaborations spanning BT, IT and NT fields to develop new products and platform technologies.
GMP-compliant manufacture and scale-up of finished-dosage pharmaceuticals, transdermal patches and other product types across multiple production sites.
Implementation of compliance and management systems including anti-bribery, compliance management, occupational health and environmental systems.
Joint research and R&D network collaborations spanning BT, IT and NT fields to develop new products and platform technologies.
GMP-compliant manufacture and scale-up of finished-dosage pharmaceuticals, transdermal patches and other product types across multiple production sites.
Implementation of compliance and management systems including anti-bribery, compliance management, occupational health and environmental systems.
Expertise Areas
- New drug discovery and formulation development
- Clinical trial management (Phases I–III)
- GMP manufacturing and scale-up
- Transdermal drug delivery systems (TDDS)
Key Technologies
- Transdermal drug delivery systems (TDDS) / patch manufacturing
- Oral anticancer formulation development
- Hyaluronic acid filler formulations
- Probiotic / postbiotic formulation
News & Updates
Regulatory approval obtained to add a breast cancer indication for 리포락셀액.
Received rare disease (orphan) designation from the European Medicines Agency for 리포락셀액.
Publication/announcement of Phase 2 clinical trial results for 리포락셀 in the United States.
Acquired multiple management system certifications including ISO14001, ISO45001 and an ESG management system certification.
Received export achievement awards including multi-million dollar export trophies and recognition for export performance.
Regulatory approval obtained to add a breast cancer indication for 리포락셀액.
Received rare disease (orphan) designation from the European Medicines Agency for 리포락셀액.
Publication/announcement of Phase 2 clinical trial results for 리포락셀 in the United States.
Acquired multiple management system certifications including ISO14001, ISO45001 and an ESG management system certification.
Received export achievement awards including multi-million dollar export trophies and recognition for export performance.